← Trials/Trial dossier/NCT00007189

CompletedPhase 3

Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

Lead sponsor

Seattle Institute for Biomedical and Clinical Research

Assets

Celecoxib / Naproxen

Listed sites

Recruiting sites

Enrollment

2,625

Study population

Alzheimer’s disease

Key I/E criterion

•Age ≥70

Primary endpoint

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDIA0026

NCT IDNCT00007189

NihU01AG015477

Timeline

Milestones

Study first posted2000-12-14estimated

Study start2001-01 (month precision)

Primary completion2007-05actual (month precision)

Last update posted2016-10-19estimated

Assets

Drug assets

Celecoxib Naproxen

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Aged 70 years or older.

•Family history of parent, brother, or sister who has, or had, serious age-related memory loss, senility, dementia, or Alzheimer's disease.

•Study partner available to provide information on the cognitive status of the participant and to assist with monitoring of trial medications, if needed.

•Sufficient fluency in written and spoken English to participate in study visits and neuropsychological testing.

•Willingness to limit use of the following for the duration of the study: vitamin E (at doses greater than 400 IU per day), non-aspirin NSAIDs, histamine H2 receptor antagonists (Tagamet, for example), corticosteroids, anti-inflammatory or analgesic doses of aspirin (greater than 81 mg per day), Ginkgo biloba extracts

•Ability and intention to participate in regular study visits, in the opinion of the study physician.

•Provision of informed consent

Exclusion criteria

•History of peptic ulcer disease with bleeding or obstruction.

•Clinically significant liver or kidney disease.

•History of hypersensitivity to aspirin, ibuprofen, celecoxib, naproxen, or other NSAIDs.

•Use of anti-coagulant medication.

•Cognitive impairment or dementia.

•Current alcohol abuse or dependence

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Publications (9)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.